The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regard-ing the treatment of non???muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Gu???erin (BCG) short-age; new roles for immune checkpoint inhibitors in non???muscle inva-sive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody???drug conjugates for metastatic bladder cancer.